*Perspective Chapter: Management of Bone Health in Breast Cancer Patients DOI: http://dx.doi.org/10.5772/intechopen.109030*

On the other hand, there is a very huge body of evidence that intravenous bisphosphonates improve outcome in postmenopausal women with early breast cancer. In a vast systematic meta-analysis by the *Early Breast Cancer Trialists Collaborative Group* EBCTCG including more than 18,000 patients, clear benefit was proven in regard to the overall reduction of recurrence (RR 0·94, 95% CI 0·87–1·01; 2p = 0·08), distant recurrence (0·82, 0·74–0·92; 2p = 0·0003), bone recurrence (0·72, 0·60–0·86; 2p = 0·0002), and breast cancer mortality (0·82, 0·73–0·93; 2p = 0·002) [10]. The authors were able to thus clearly demonstrate the advantages of bisphosphonate administration in postmenopausal women. Therefore, it quickly became a worldwide current standard to use bisphosphonates in management of early breast cancer, stages I–III. Current indications, dosage, and toxicity are displayed in **Table 1**.


*p.o. = oral; mo = months.*

### **Table 1.**

*Indication, dosing, and toxicity of bone-targeted agents (adapted from Biskup [1, 20]).*
